PDF(Pubmed)
Abstract：
Heterotopic ossification refers to the pathological formation of extra-skeletal bone. It is a common complication of trauma or surgery that can cause disability and has no definitive cure. Furthermore, the mechanisms underlying chronic inflammation during ossification remain unclear. Therefore, this study aimed to elucidate the systemic immune microenvironment status of heterotopic ossification and identify biomarkers of therapeutic efficacy and recurrence. A combination of stereoarthrolysis with prophylactic radiotherapy and non-steroidal anti-inflammatory drugs was used to treat patients with heterotopic ossification. Changes were observed in peripheral blood lymphocyte levels after treatment. The number of IFNγ+CD8+T cells (3.753 % vs 12.90 %, P < 0.0001) and IL17+CD4+T cells (3.420 % vs 5.560 %, P = 0.0281) were was higher in the peripheral blood of relapsed patients with heterotopic ossification than in that of non-relapsed patients. Similarly, the number of these cells was elevated in patients who developed heterotopic ossification after posttraumatic elbow surgery. Peripheral CD8+T cells derived from patients with this pathology promoted osteogenesis through IFNγ expression in vitro. Our findings demonstrate that IFNγ+CD8+T cells and IL17+CD4+T cells are potential biomarkers of heterotopic ossification after posttraumatic elbow surgery. Furthermore, these cells can be used to predict therapeutic efficacy and relapse after combination therapy.
摘要：
异位骨化是指骨骼外骨的病理形成。它是创伤或手术的常见并发症，可导致残疾，并且没有明确的治愈方法。此外，骨化过程中慢性炎症的潜在机制尚不清楚.因此,本研究旨在阐明异位骨化的全身免疫微环境状态，并确定治疗效果和复发的生物标志物。立体关节溶解术与预防性放疗和非甾体抗炎药的组合用于治疗异位骨化患者。观察治疗后外周血淋巴细胞水平的变化。IFNγ+CD8+T细胞数（3.753%vs12.90%，P<0.0001）和IL17+CD4+T细胞（3.420％vs5.560％，P=0.0281）在异位骨化复发患者的外周血中高于非复发患者。同样，在创伤后肘关节手术后发生异位骨化的患者中,这些细胞的数量升高.来自患有这种病理的患者的外周CD8+T细胞在体外通过IFNγ表达促进骨生成。我们的研究结果表明，IFNγ+CD8+T细胞和IL17+CD4+T细胞是创伤后肘关节术后异位骨化的潜在生物标志物。此外，这些细胞可用于预测联合治疗后的疗效和复发。
